Administration, Intravaginal
Animals
Biological Transport
/ drug effects
Cell Line, Tumor
Darunavir
/ administration & dosage
Disease Models, Animal
Drug Compounding
/ methods
Female
HIV Infections
/ prevention & control
HIV Protease Inhibitors
/ administration & dosage
HIV-1
Humans
Macaca fascicularis
Multidrug Resistance-Associated Protein 2
Multidrug Resistance-Associated Proteins
/ genetics
Tenofovir
/ administration & dosage
Tissue Distribution
Up-Regulation
/ drug effects
Vagina
/ metabolism
darunavir
macaques
microbicides
multidrug resistance associated protein
tenofovir
vagina
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
02 03 2020
02 03 2020
Historique:
pubmed:
6
2
2020
medline:
27
5
2021
entrez:
5
2
2020
Statut:
ppublish
Résumé
Clinical trials have demonstrated partial protection against HIV-1 infection by vaginal microbicide formulations based on antiretroviral (ARV) drugs. Improved formulations that will maintain sustained drug concentrations at viral target sites in the cervicovaginal mucosa are needed. We have previously demonstrated that treatment of cervicovaginal cell lines with ARV drugs can alter gene expression of drug transporters, suggesting that the mucosal disposition of ARV drugs delivered vaginally can be modulated by drug transporters. This study aimed to investigate
Identifiants
pubmed: 32017579
doi: 10.1021/acs.molpharmaceut.9b01121
doi:
Substances chimiques
ABCC2 protein, human
0
HIV Protease Inhibitors
0
Multidrug Resistance-Associated Protein 2
0
Multidrug Resistance-Associated Proteins
0
Tenofovir
99YXE507IL
Darunavir
YO603Y8113
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM